Responses
ORIGINAL ARTICLE
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance
Compose a Response to This Article
Other responses
No responses have been published for this article.